As of August 1, 2022, Sequence Listing submitted to the Taiwan Intellectual Property Office (IPO) for an invention patent application comprising nucleotide or amino acid sequence(s) shall be drafted in accordance with the WIPO ST.26 format.

　WIPO announced that as of July 1, 2022, for an international patent application filed under Patent Cooperation Treaty (PCT) comprising Sequence Listing, the Sequence Listing shall be drafted in accordance with the WIPO ST.26 format. For facilitating global data exchange and search, the Taiwan IPO will fully implement the WIPO ST.26 format as of August 1, 2022. Sequence Listing submitted to the Taiwan IPO for an invention patent application filed on or after August 1, 2022 comprising nucleotide or amino acid sequence(s) shall be drafted in accordance with the WIPO ST.26 format. In view of the applicant’s behalf in filing an international patent application, the Taiwan IPO accepts that Sequence Listing submitted for an invention patent application filed between July 1, 2022 and July 31, 2022 comprising nucleotide or amino acid sequence(s) can be drafted in accordance with either the current WIPO ST.25 format or the WIPO ST.26 format.  

　WIPO provides a desktop application named “WIPO Sequence” for enabling the applicant to compile a Sequence Listing meeting the WIPO ST.26 format (see the website: https://www.wipo.int/standards/en/sequence ).  (Released 2022.06.08)